BioArctic

BioArctic Deferred Tax Liabilities

The Deferred Tax Liabilities of BioArctic (BIOA B.ST) as of Nov 9, 2026 is 59.02 M SEK.

Deferred Tax Liabilities

59.02 MSEK

Last updated:

Deferred Tax Liabilities of BioArctic is 2025 59.02 M SEK. Deferred Tax Liabilities of BioArctic was 2024 0.00 SEK. It decreases by % higher compared to the previous year.

The BioArctic Deferred Tax Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Deferred Tax Liabilities
Date
Deferred Tax Liabilities
Jan 1, 2017
5.49 M SEK
Jan 1, 2018
32.52 M SEK
Jan 1, 2019
38.69 M SEK
Jan 1, 2020
20.67 M SEK
Jan 1, 2021
0.00 SEK
Jan 1, 2023
12.39 M SEK
Jan 1, 2024
0.00 SEK
Jan 1, 2025
59.02 M SEK
The BioArctic Deferred Tax Liabilities history
YEARDeferred Tax LiabilitiesYoY
59.02 MSEK—
0.00SEK-100.00%
12.39 MSEK—
0.00SEK-100.00%
20.67 MSEK-46.58%
38.69 MSEK+18.96%
32.52 MSEK+492.67%
5.49 MSEK+32.66%
4.14 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Deferred Tax Liabilities of BioArctic is 59.02 M SEK in 2025.

On Eulerpool you can find the complete historical development of Deferred Tax Liabilities BioArctic since 2006 – with annual values, charts, and detailed analysis.

Deferred tax liabilities arise from temporary differences between accounting and tax treatments. They represent taxes owed in the future on income already recognized.

Deferred Tax Liabilities's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Deferred Tax Liabilities's BioArctic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — BioArctic

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — BioArctic